tradingkey.logo
搜索

ENDRA Life Sciences Inc

NDRA
添加自选
4.610USD
+0.280+6.47%
收盘 07-31 16:00美东报价延迟15分钟
5.42M总市值
亏损市盈率 TTM

ENDRA Life Sciences Inc

4.610
+0.280+6.47%

关于 ENDRA Life Sciences Inc 公司

ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.

ENDRA Life Sciences Inc简介

公司代码NDRA
公司名称ENDRA Life Sciences Inc
上市日期Jun 28, 2017
CEOTokman (Alexander Y)
员工数量21
证券类型Ordinary Share
年结日Jun 28
公司地址3600 Green Ct Ste 350
城市ANN ARBOR
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编48105
电话17343350468
网址https://www.endrainc.com/
公司代码NDRA
上市日期Jun 28, 2017
CEOTokman (Alexander Y)

ENDRA Life Sciences Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Anthony DiGiandomenico
Mr. Anthony DiGiandomenico
Independent Director
Independent Director
76.27K
+7.06%
Mr. Richard Jacroux
Mr. Richard Jacroux
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
33.46K
+40.23%
Mr. Alexander Y. Tokman
Mr. Alexander Y. Tokman
Chairman of the Board, Acting Chief Executive Officer
Chairman of the Board, Acting Chief Executive Officer
5.00
-1500000.00%
Mr. Michael Harsh
Mr. Michael Harsh
Independent Director
Independent Director
2.00
-3016200.00%
Mr. Louis J. Basenese
Mr. Louis J. Basenese
Independent Director
Independent Director
--
--
Ms. Yvonne Briggs
Ms. Yvonne Briggs
Investor Relations
Investor Relations
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Anthony DiGiandomenico
Mr. Anthony DiGiandomenico
Independent Director
Independent Director
76.27K
+7.06%
Mr. Richard Jacroux
Mr. Richard Jacroux
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
33.46K
+40.23%
Mr. Alexander Y. Tokman
Mr. Alexander Y. Tokman
Chairman of the Board, Acting Chief Executive Officer
Chairman of the Board, Acting Chief Executive Officer
5.00
-1500000.00%
Mr. Michael Harsh
Mr. Michael Harsh
Independent Director
Independent Director
2.00
-3016200.00%
Mr. Louis J. Basenese
Mr. Louis J. Basenese
Independent Director
Independent Director
--
--
Ms. Yvonne Briggs
Ms. Yvonne Briggs
Investor Relations
Investor Relations
--
--

常见问题

ENDRA Life Sciences Inc的前五大股东是谁?

ENDRA Life Sciences Inc 的前五大股东如下:Mr. Anthony DiGiandomenico

有多少机构持有ENDRA Life Sciences Inc(NDRA)的股份?

截至2026Q1,共有30家机构持有ENDRA Life Sciences Inc的股份,合计持有的股份价值约为218.33K,占公司总股份的17.60%。与2025Q4相比,机构持股有所增加,增幅为137855.00。
tradingkey.logo
风险提示:我们的网站和移动应用程序仅提供关于某些投资产品的一般信息。Finsights 不提供财务建议或对任何投资产品的推荐,且提供此类信息不应被解释为 Finsights 提供财务建议或推荐。
投资产品存在重大投资风险,包括可能损失投资的本金,且可能并不适合所有人。投资产品的过去表现并不代表其未来表现。
Finsights 可能允许第三方广告商或关联公司在我们的网站或移动应用程序的任何部分放置或投放广告,并可能根据您与广告的互动情况获得报酬。
© 版权所有: FINSIGHTS MEDIA PTE. LTD. 版权所有